Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
European Journal of Nuclear Medicine and Molecular Imaging
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 10/2010

01.10.2010 | Original Article

Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib

verfasst von: Bernd Kasper, Antonia Dimitrakopoulou-Strauss, Ludwig G. Strauss, Peter Hohenberger

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We used 18F-FDG PET to evaluate the FDG uptake in patients with aggressive fibromatosis (AF, also known as desmoid tumours) undergoing therapy with imatinib (imatinib mesylate, Glivec).

Methods

The pilot study included nine patients with progressive AF receiving oral treatment with imatinib at a daily dose of 800 mg. Patients were examined using PET prior to the start of therapy and during imatinib treatment. Restaging according to the Response Evaluation Criteria in Solid Tumors (RECIST) was performed in parallel using CT and/or MRI and served as reference.

Results

The clinical outcomes in nine evaluable patients were as follows: seven patients with stable disease, and two patients with progressive disease. A 27% decrease in the median average standardized uptake value (SUV) of the sequential PET examinations was demonstrated in all evaluable patients with three patients (33%) showing a decrease in SUV of more than 40% (48%, 52% and 54%, respectively); no patient showed a substantial increase in SUV.

Conclusion

To our knowledge, this is the first series of AF patients undergoing treatment with imatinib and monitored using sequential PET imaging, that allows detection of SUV changes after imatinib induction, thus helping to decide whether treatment should be continued or not.
Literatur
1.
2.
Micke O, Seegenschmiedt MH. Radiation therapy for aggressive fibromatosis (desmoid tumors): results of a national patterns of care study. Int J Radiat Oncol Biol Phys 2005;61:882–91.PubMed
3.
Bertario L, Russo A, Sala P, Varesco L, Giarola M, Mondini P, et al. Hereditary colorectal tumor registry. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003;21:1698–707.CrossRefPubMed
4.
Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg 1996;83:1494–504.CrossRefPubMed
5.
Janinis J, Patriki M, Vini L, Aravantinos G, Whelan JS. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003;14:181–90.CrossRefPubMed
6.
Pignatti G, Barbanti-Bròdano G, Ferrari D, Gherlinzoni F, Bertoni F, Bacchini P, et al. Extraabdominal desmoid tumor. A study of 83 cases. Clin Orthop Relat Res 2000;375:207–13.CrossRefPubMed
7.
Knudsen AL, Bülow S. Desmoid tumour in familial adenomatous polyposis. A review of literature. Fam Cancer 2001;1:111–9.CrossRefPubMed
8.
Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY, ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19 Suppl 2:ii89–93.CrossRefPubMed
9.
Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–6.CrossRefPubMed
10.
qqHeinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925–32.PubMed
11.
Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172–87.CrossRefPubMed
12.
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.CrossRefPubMed
13.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80.CrossRefPubMed
14.
qqHeinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–9.CrossRefPubMed
15.
qqHeinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708–10.CrossRefPubMed
16.
Mace J, Sybill BJ, Sondak V, McGinn C, Hayes C, Thomas D, et al. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer 2002;95:2373–9.CrossRefPubMed
17.
Leithner A, Gapp M, Radl R, Pascher A, Krippl P, Leithner K, et al. Immunohistochemical analysis of desmoid tumours. J Clin Pathol 2005;58:1152–6.CrossRefPubMed
18.
qqHeinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumour). J Clin Oncol 2006;24:1195–203.CrossRefPubMed
19.
Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, Guillemet C, Cupissol D, et al. Imatinib for the treatment of aggressive fibromatosis (desmoid tumors) failing local treatment. A phase II trial of the French Sarcoma Group. ASCO Meeting Abstracts 2006, 24:9516.
20.
Dufresne A, Penel N, Salas S, Le Cesne A, Perol D, Bui B, et al. Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoid tumor): A FNCLCC/French Sarcoma Group phase II trial. ASCO Meeting Abstracts 2009, 27:10518.
21.
Chugh R, Maki RG, Thomas DG, Reinke D, Wathen JK, Patel S, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. ASCO Meeting Abstracts 2006, 24:9515.
22.
Wendtner CM, Abdel-Rahman S, Krych M, Baumert J, Lindner LH, Baur A, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 2002;20:3156–64.CrossRefPubMed
23.
Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1991;32:623–48.PubMed
24.
Schulte M, Brecht-Krauss D, Heymer B, Guhlmann A, Hartwig G, Sarkar MR, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumors: is a non-invasive determination of biological activity possible? Eur J Nucl Med Mol Imaging 1999;26:599–605.CrossRef
25.
Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med 1998;39:250–4.PubMed
26.
Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU 3rd, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339–48.CrossRefPubMed
27.
Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol 2006;18:369–73.CrossRefPubMed
28.
Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984;33:37–42.CrossRefPubMed
29.
Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, et al. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg 2005;241:286–94.CrossRefPubMed
30.
Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519–27.PubMed
31.
Burger C, Buck A. Requirements and implementation of a flexible kinetic modeling tool. J Nucl Med 1997;38:1818–23.PubMed
32.
Cheng EY, Froelich JW, Manivel JC, Weigel J, Skubitz KM. Correlation of FDG PET-CT with histologic response after neoadjuvant chemotherapy for soft tissue sarcomas. ASCO Meeting Abstracts 2009, 27:10583.
33.
Kasper B, Dietrich S, Dimitrakopoulou-Strauss A, Strauss LG, Haberkorn U, Ho AD, et al. Early prediction of therapy outcome in patients with high risk soft tissue sarcoma using positron emission tomography. Onkologie 2008;31:107–12.CrossRefPubMed
34.
Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004;25:433–8.CrossRefPubMed
35.
Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S–50S.CrossRefPubMed
36.
Ramos-Font C, Santiago Chinchilla A, Rebollo Aguirre AC, Rodríguez Fernández A, Medina Benítez A, Llamas Elvira JM. Desmoid tumor of the thoraco-abdominal wall characterized with 18F-fluorodeoxyglucose PET/CT scan. Correlation with magnetic resonance and bone scintigraphy. Review of the literature. Rev Esp Med Nucl 2009;28:70–3.CrossRefPubMed
37.
Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Schmitt T, Haberkorn U, et al. Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. Eur J Nucl Med Mol Imaging 2010. doi:10.​1007/​s00259-010-1435-z.
38.
Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, et al. Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med 2010;51:551–8.CrossRefPubMed
Metadaten
Titel
Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib
verfasst von
Bernd Kasper
Antonia Dimitrakopoulou-Strauss
Ludwig G. Strauss
Peter Hohenberger
Publikationsdatum
01.10.2010
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 10/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-010-1498-x

Weitere Artikel der Ausgabe 10/2010

European Journal of Nuclear Medicine and Molecular Imaging 10/2010 Zur Ausgabe

Society communications

EANM YIM 2010—Report

Original Article

Real-time breath-hold triggering of myocardial perfusion imaging with a novel cadmium-zinc-telluride detector gamma camera

Original Article

Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters

Image of the Month

Before and after treatment 18F-FDG PET/CT images in a patient with cutaneous T-cell lymphoma

Guidelines

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE

Original Article

PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG